Arrotex moves into dermatitis

Arrotex is targeting a huge market with its latest innovative product to hit the PBS, a powerful treatment for skin treatments that are resistant to lower potency topical treatments.

Xobet will be the most potent PBS-listed topical corticosteroid indicated for corticosteroid-responsive dermatoses that are resistant to lower potency topical corticosteroid therapy after being listed in May.

"The availability of a super-potent topical steroid in Australia has added a powerful tool to the armamentarium of Australian dermatologists in managing inflammatory dermatoses," Liverpool Hospital Department of Dermatology Head, Associate Professor Monisha Gupta, said.